natgillin/translations-raw huggingface dataset:
In the initial three-year, randomised, double-blind, placebo-controlled, fracture study (MF 4411), a statistically significant and medically relevant decrease in the incidence of new radiographic morphometric and clinical vertebral fractures was demonstrated (table 3).
U inicijalnom trogodišnjem randomiziranom, dvostruko slijepom, placebo kontroliranom ispitivanju prijeloma (MF 4411) dokazano je da postoji statistički značajno i medicinski relevantno smanjenje pojave novih prijeloma kralježaka utvrđenih rendgenski, morfometrički i klinički (tablica 3).
Further, as protein binding of ibandronic acid is approximately 87% at therapeutic concentrations, hypoproteinaemia in severe liver disease is unlikely to lead to clinically significant increases in free plasma concentration.
Nadalje, budući da pri terapijskim koncentracijama vezanje ibandronatne kiseline za proteine plazme iznosi otprilike 87%, nije vjerojatno da će hipoproteinemija u bolesnika s teškom bolesti jetre dovesti do klinički značajnih povećanja koncentracije slobodne ibandronatne kiseline u plazmi.
If you are taking a tablet each day, skip the missed dose completely.
Ako uzimate jednu tabletu dnevno, preskočite propuštenu dozu.
Female patients with breast cancer and radiologically confirmed bone metastases were randomised to receive placebo (277 patients) or 50 mg ibandronic acid (287 patients).
Bolesnice s rakom dojke i radiološki potvrđenim koštanim metastazama randomizirane su za primanje placeba (277 bolesnica) ili 50 mg ibandronatne kiseline (287 bolesnica).
Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation.
Ibandronatna kiselina eliminira se isključivo renalnom sekrecijom i nije podložna nikakvom obliku biotransformacije.
- Water is the only drink that should be taken with Ibandronic Acid Teva.
- Voda je jedino piće s kojim se Ibandronatna kiselina Teva smije uzimati.
One year data in study BM 16549 Two year data in study BM
Podaci iz ispitivanja BM 16549 nakon dvije godine
Metabolism and nutrition disorders
Poremećaj metabolizma i prehrane
What Ibandronic Acid Teva is and what it is used for
Što je Ibandronatna kiselina Teva i za što se koristi
If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor about your dental treatment and tell your dentist that you are being treated with Ibandronic Acid Teva.
Ako ste podvrgnuti liječenju zuba ili se morate podvrgnuti stomatološkom kirurškom zahvatu (npr. vađenju zuba), obavijestite svog liječnika o liječenju zuba i recite svom stomatologu da se liječite lijekom Ibandronatna kiselina Teva.
Bone resorption due to malignant disease is characterized by excessive bone resorption that is not balanced with appropriate bone formation.
Resorpcija kostiju uzrokovana zloćudnom bolesti karakterizirana je pretjeranom resorpcijom kostiju koja nije uravnotežena s odgovarajućim formiranjem kostiju.
This regimen reduced the occurrence of new radiographic vertebral fractures by 62 % (p=0.0001) over the three year duration of the study.
Takvo je liječenje smanjilo pojavu novih rendgenskih vidljivih prijeloma kralježaka za 62% (p=0,0001) u razdoblju od tri godine, koliko je trajalo ispitivanje.
Bone mineral density (BMD)
Mineralna gustoća kosti (BMD - Bone mineral density)
- If you have any swallowing or digestive problems.
- Ako imate problema s gutanjem ili probavom.
Water may be taken at any time during the course of Ibandronic Acid Teva treatment (see section 4.5).
Voda se smije uzimati bilo kada za vrijeme trajanja liječenja Ibandronatnom kiselinom Teva (vidjeti dio 4.5).
Biochemical markers of bone turnover (such as urinary CTX and serum Osteocalcin) showed the expected pattern of suppression to premenopausal levels and reached maximum suppression within a period of 3-6 months.
Biokemijski biljezi koštane pregradnje (kao što je CTX u urinu i serumski osteokalcin) pokazali su očekivani obrazac snižavanja do premenopauzalnih razina te su dosegnuli najviše sniženje tijekom 3 do 6 mjeseci.
Table 2: Mean relative change from baseline of lumbar spine, total hip, femoral neck and trochanter BMD after one year (primary analysis) and two years of treatment (Per-Protocol Population) in study BM 16549.
Tablica 2: Srednja relativna vrijednost promjene od početne vrijednosti BMD lumbalne kralježnice, cijelog kuka, vrata bedrene kosti i trohantera nakon jedne godine (primarna analiza) i dvije godine liječenja (populacija po protokolu) u ispitivanju BM 16549.
In the overall patient population of the study MF 4411, no reduction was observed for non-vertebral fractures, however daily ibandronic acid appeared to be effective in a high-risk subpopulation (femoral neck BMD T-score < -3.0), where a non-vertebral fracture risk reduction of 69 % was observed.
U ukupnoj populaciji bolesnika ispitivanja MF4411 nije uočeno smanjenje broja nevertebralnih prijeloma, no čini se da je dnevna doza ibandronata djelotvorna u visokorizičnoj populacijskoj podskupini (T-vrijednost BMD za vrat bedrene kosti < -3,0), u kojoj je primijećeno smanjenje rizika od nevertebralnih prijeloma za 69%.
The inhibition of endogenous bone resorption has also been documented by 45Ca kinetic studies and by the release of radioactive tetracycline previously incorporated into the skeleton.
Inhibicija endogene resorpcije kosti dokazana je i u kinetskim ispitivanjima s 45Ca te otpuštanjem radioaktivnog tetraciklina prethodno ugrađenog u skelet.
The strong effect on vertebral fractures was furthermore reflected by a statistically significant reduction of height loss compared to placebo (p<0.0001).
Značajan učinak na prijelome kralježaka dodatno ukazuje i statistički značajno smanjenje gubitka visine u usporedbi s placebom (p<0,0001).
If you have severe kidney problems, your doctor may reduce your dose to one tablet each week.
Ako imate tešku bolest bubrega liječnik vam može smanjiti dozu na jednu tabletu tjedno.
Ibandronic acid 2.5 mg administered daily, showed a statistically significant and medically relevant reduction in the incidence of new vertebral fractures.
Ibandronatna kiselina 2,5 mg primijenjena dnevno pokazala je statistički značajno i medicinski relevantno smanjenje pojave novih prijeloma kralježaka.
After initial systemic exposure, ibandronic acid rapidly binds to bone or is excreted into urine.
Nakon početne sistemske izloženosti, ibandronatna kiselina se vrlo brzo veže uz kost ili se izlučuje u urin.
Medicinal products and supplements (including calcium) should similarly be avoided prior to taking Ibandronic Acid Teva tablets.
Lijekove i nadomjesne pripravke (uključujući kalcij) također bi trebalo izbjegavati prije uzimanja tableta Ibandronatne kiseline Teva.
• itching, swelling of your face, lips, tongue and throat, with difficulty breathing.
• svrbež, oticanje lica, usana, jezika i grla, uz otežano disanje.
• severe pain in the chest, severe pain after swallowing food or drink, severe nausea, or vomiting, difficulty in swallowing.
• jaka bol u prsima, jaka bol nakon gutanja hrane ili pića, jaka mučnina ili povraćanje, otežano gutanje.
This includes: - eating a balanced diet rich in calcium and vitamin D, - walking or any other weight-bearing exercise, - not smoking; and not drinking too much alcohol.
Takav način obuhvaća: - uravnoteženu prehranu bogatu kalcijem i vitaminom D - kretanje i druge tjelesne aktivnosti - nepušenje i nekonzumiranje prekomjernih količina alkohola.
Caution is advised when bisphosphonates are administered with aminoglycosides, since both substances can lower serum calcium levels for prolonged periods.
Potreban je oprez pri primjeni bisfosfonata s aminoglikozidima, budući da obje tvari mogu smanjiti razine kalcija u serumu na dulje vrijeme.
- Swallow your tablet whole, - do not chew it, crush it or let it dissolve in your mouth.
- Tabletu progutajte cijelu - nemojte je žvakati, drobiti ili otapati u ustima.
Do not take Ibandronic Acid Teva if you are pregnant, planning to get pregnant or if you are breast-feeding.
Ne uzimajte Ibandronatnu kiselinu Teva ako ste trudni, planirate zatrudnjeti ili ako dojite.
Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw.
Odmah se obratite svom liječniku i stomatologu ako primijetite bilo kakve tegobe s ustima ili zubima, poput rasklimanih zuba, boli ili oticanja, ranica koje ne cijele ili iscjetka, jer bi to mogli biti znakovi osteonekroze čeljusti.
No dose adjustment is necessary for patients with mild or moderate renal impairment (CLcr equal or greater than 30 ml/min), as shown in study BM 16549 where the majority of patients had mild to moderate renal impairment.
Nisu potrebne prilagodbe doze za bolesnike s blagim ili umjerenim oštećenjem funkcije bubrega (CLcr jednak ili veći od 30 ml/min), kao što pokazuje studija BM 16549, u kojoj je većina bolesnika imala blago do umjereno oštećenje funkcije bubrega.
Other things that can increase the risk of fractures include: - not enough calcium and vitamin D in the diet, - smoking, or drinking too much alcohol, - not enough walking or other weight-bearing exercise, - a family history of osteoporosis.
Ostali faktori koji mogu povećati rizik od osteoporoze su: - nedovoljno kalcija i vitamina D u prehrani - pušenje ili prekomjerno konzumiranje alkohola - nedovoljno kretanja ili nedostatak drugih tjelesnih aktivnosti - oboljeli od osteoporoze u obitelji.
The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections.
Mogućnost osteonekroze vanjskog slušnog kanala potrebno je razmotriti u bolesnika koji primaju bisfosfonate, a koji imaju simptome koji zahvaćaju uho uključujući kronične infekcije uha.
Calcium supplements, antacids and some oral medicinal products containing multivalent cations
Suplementi kalcija, antacidi i neki peroralni lijekovi koji sadrže multivalentne katione
Once you've eaten, it's OK to lie down if you wish, and to take any other medication you need.
Ako želite, nakon jela možete leći ili uzeti druge lijekove koje morate uzeti.
In this study, ibandronic acid was evaluated at oral doses of 2.5 mg daily and 20 mg intermittently as an exploratory regimen.
U ovom ispitivanju, ibandronatna kiselina je ispitivana u oralnoj dozi od 2,5 mg jedanput dnevno i u intermitentnoj dozi od 20 mg kao eksplorativni režim primjene.
Talk to a nurse or a doctor straight away if you notice any of the following serious side effectsyou may need urgent medical treatment:
Razgovarajte odmah s medicinskom sestrom ili liječnikom ako primijetite bilo koju od slijedećih ozbiljnih nuspojava - možda će Vam biti potrebna hitna medicinska pomoć:
- The tablets should be swallowed whole with a full glass of water (180 to 240 ml) while the patient is standing or sitting in an upright position.
- Tablete treba progutati cijele uz punu čašu vode (180 do 240 ml) dok bolesnik stoji ili sjedi u uspravnom položaju.
While on treatment, invasive dental procedures should be performed only after careful consideration and be avoided in close proximity to Ibandronic Acid Teva administration.
Tijekom liječenja, invazivne stomatološke zahvate treba provoditi tek nakon pažljivog razmatranja, a izbjegavati ih u razdoblju blizu vremena primjene lijeka Ibandronatna kiselina Teva.
The usual dose of Ibandronic Acid Teva is one tablet each day.
Uobičajena doza Ibandronatne kiseline Teva je jedna tableta dnevno.
After swallowing your monthly Ibandronic Acid Teva tablet, wait for 1 hour before taking any other medication, including indigestion tablets, calcium supplements, or vitamins.
Kada progutate svoju mjesečnu tabletu Ibandronatne kiseline Teva, pričekajte jedan sat prije uzimanja bilo kojeg drugog lijeka, uključujući tablete za probavne smetnje te preparate koji sadrže kalcij, ili vitamine.
Take Ibandronic Acid Teva with at least 6 hours after you had last had anything to eat, drink or any other medicines or supplements (e.g. products containing calcium (milk), aluminium, magnesium and iron) except water.
Ibandronatnu kiselinu Teva uzmite najmanje 6 sati nakon zadnjeg obroka, pića ili nekog drugog lijeka ili dodatka (primjerice proizvoda koji sadržavaju kalcij (mlijeko), aluminij, magnezij i željezo), osim vode.
In a Phase 1 bioequivalence study conducted in 72 postmenopausal women receiving 150 mg orally every 28 days for a total of four doses, inhibition in serum CTX following the first dose was seen as early as 24 hours post-dose (median inhibition 28 %), with median maximal inhibition (69 %) seen 6 days later.
U fazi I ispitivanja bioekvivalencije provedenog u 72 postmenopauzalne žene koje su primale 150 mg peroralno svakih 28 dana do ukupno četiri doze, inhibicija serumskog CTX nakon prve doze uočena je već 24 sata nakon primanja doze (medijan inhibicije 28%), dok je medijan najviše inhibicije (69%) uočen 6 dana kasnije.
- If you forgot to take your tablet on your chosen day and your next scheduled dose is only 1 to 7 days away…
Ako ste zaboravili uzeti tabletu na odabran dan, a sljedeću dozu trebate uzeti za samo 1 do 7 dana…
While being treated, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups.
Tijekom liječenja morate održavati dobru higijenu usne šupljine (što uključuje redovito pranje zuba) i redovito odlaziti na kontrolne stomatološke preglede.
As renal function decreases with age, this is the only factor to take into consideration (see renal impairment section).
Kako se bubrežna funkcija smanjuje s godinama, to je jedini faktor koji treba uzeti u obzir (vidjeti odjeljak o oštećenju bubrega).
There was no evidence for a direct foetal toxic or teratogenic effect of ibandronic acid in orally treated rats and rabbits and there were no adverse effects on the development in F1 offspring in rats at an extrapolated exposure of at least 35 times above human exposure.
Nije bilo dokaza izravne toksičnosti za plod ili teratogenog učinka u štakora i zečeva kojima je ibandronatna kiselina primijenjena peroralno niti je bilo nuspojava vezanih uz razvoj u F1 potomstva štakora pri izloženosti dozi dobivenoj ekstrapolacijom barem 35 puta većoj od maksimalno dopuštene izloženosti u ljudi.
Existing hypocalcaemia must be corrected before starting Ibandronic Acid Teva therapy.
Postojeća hipokalcijemija mora se korigirati prije početka terapije Ibandronatnom kiselinom Teva.
Some people need to be especially careful while they're taking Ibandronic Acid Teva.
Neki ljudi trebaju biti osobito oprezni pri uzimanju Ibandronatne kiseline Teva.
Gastrointestinal irritation
Gastrointestinalna iritacija
In animal models ibandronic acid produced biochemical changes indicative of dose-dependent inhibition of bone resorption, including suppression of urinary biochemical markers of bone collagen degradation (such as deoxypyridinoline, and cross-linked N-telopeptides of type I collagen (NTX)).
Ibandronatna kiselina u životinjskim modelima uzrokuje biokemijske promjene povezane s inhibicijom resorpcije kosti ovisnom o dozi, uključujući supresiju biokemijskih biljega razgradnje koštanog kolagena (kao što je deoksipiridinolin i poprečno vezani N-telopeptidi kolagena tipa I (NTX)) u urinu.
In studies in rats using the intravenous route, ibandronic acid decreased fertility at high daily doses (see section 5.3).
U ispitivanjima na štakorima koji su lijek primali intravenski, ibandronatna je kiselina smanjila plodnost pri visokim dnevnim dozama (vidjeti dio 5.3).
Do not take Ibandronic Acid Teva with food.
Ne uzimajte Ibandronatnu kiselinu Teva s hranom.
Protein binding in human plasma is approximately 87% at therapeutic concentrations, and thus interaction with other medicinal products, due to displacement is unlikely.
Vezanje za proteine plazme u ljudi iznosi otprilike 87% pri terapijskim koncentracijama, i stoga interakcija s drugim lijekovima zbog istiskivanja nije vjerojatna.
Osteoporosis is a thinning and weakening of the bones, which is common in women after the menopause.
Osteoporoza je bolest koja dovodi do stanjenja i slabljenja kosti, a uobičajena je u žena u postmenopauzi.
In humans, the efficacy of both daily and intermittent administration with a dose-free interval of 9-10 weeks of ibandronic acid was confirmed in a clinical trial (MF 4411), in which ibandronic acid demonstrated anti-fracture efficacy.
U ljudi je djelotvornost dnevne i intermitentne primjene s intervalom od 9 do 10 tjedana bez primanja doze ibandronatne kiseline potvrđena kliničkim ispitivanjem (MF 4411), u kojemu je ibandronatna kiselina pokazala djelotvornost u sprečavanju prijeloma.
- If you forgot to take your tablet on your chosen day and your next scheduled dose is more than 7 days away…
Ako ste zaboravili uzeti tabletu na odabran dan, a sljedeću dozu trebate uzeti za više od 7 dana…
Increases at the hip compared to baseline were 2.8 % at the femoral neck, 3.4 % at the total hip, and 5.5 % at the trochanter.
Povećanja mineralne gustoće kosti kuka u usporedbi s početnim vrijednostima iznosila su 2,8 % za vrat bedrene kosti, 3,4 % za cijeli kuk i 5,5 % za trohanter.
Efficacy results are summarised in Table 2.
Rezultati djelotvornosti sažeto su prikazani u tablici 2.
If you take more Ibandronic Acid Teva than you should If you've taken more than one tablet by mistake, drink a full glass of milk and talk to your doctor straight away.
Ako ste greškom uzeli više od jedne tablete, popijte cijelu čašu mlijeka i odmah konzultirajte svog liječnika.
Ibandronic acid was taken 60 minutes before the first food or drink of the day (post-dose fasting period).
Ibandronatna kiselina se uzimala 60 minuta prije uzimanja prvog obroka ili pića (razdoblje gladovanja nakon doze).
Orally administered bisphosphonates may cause local irritation of the upper gastrointestinal mucosa.
Peroralno primijenjeni bisfosfonati mogu uzrokovati lokalnu iritaciju sluznice gornjeg dijela gastrointestinalnog trakta.
Three-year lumbar spine BMD increase compared to placebo was 5.3 % and 6.5 % compared to baseline.
Nakon tri godine uočeno je povećanje BMD lumbalne kralježnice u usporedbi s placebom od 5,3 % i 6,5 % naspram početnih vrijednosti.
Keep out of the sight and reach of children.
Čuvati izvan pogleda i dohvata djece
Cases of anaphylactic reaction/shock, including fatal events, have been reported in patients treated with intravenous ibandronic acid.
Slučajevi anafilaktičke reakcije/šoka, uključujući događaje sa smrtnim ishodom, prijavljeni su u bolesnika liječenih intravenski primijenjenom ibandronatnom kiselinom.
StevensJohnson syndrome†, erythema multiforme†, dermatitis bullous†
StevensJohnsonov sindrom†, multiformni eritem†, bulozni dermatitis†
Their selective action on bone tissue is based on the high affinity of bisphosphonates for bone mineral.
Njihovo selektivno djelovanje na koštano tkivo temelji se na visokom afinitetu bisfosfonata prema mineralima koji se nalaze u kostima.
- Tablets should be swallowed whole with a glass of water (180 to 240 ml) while the patient is sitting or standing in an upright position.
- Tabletu treba progutati cijelu uz čašu obične vode (180 do 240 ml) dok bolesnik stoji ili sjedi u uspravnom položaju.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU KUTIJA
If you develop these symptoms, stop taking Ibandronic Acid Teva and tell your doctor straight away (see sections 3 and 4).
Ako se ovi simptomi pojave, prekinite uzimati Ibandronatnu kiselinu Teva i odmah se obratite svom liječniku (vidjeti dijelove 3 i 4).
• inflammation of the duodenum (first section of the bowel) causing stomach pain
• upala dvanaesnika (prvog dijela crijeva), koja uzrokuje bol u želucu
Nevertheless, according to clinical assessment of the individual patient, it is recommended that renal function, serum calcium, phosphate and magnesium should be monitored in patients treated with Ibandronic Acid Teva.
Unatoč tome, na temelju kliničke procjene za pojedinog bolesnika, preporučuje se praćenje bubrežne funkcije te kalcija, fosfata i magnezija u serumu, u bolesnika koji se liječe lijekom Ibandronatna kiselina Teva.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Unutar svake skupine učestalosti nuspojave su navedene u padajućem nizu prema ozbiljnosti.
Protein binding in human plasma is approximately 85 %-87 % (determined in vitro at therapeutic concentrations), and thus there is a low potential for interaction with other medicinal products due to displacement.
Vezanje na proteine plazme iznosi otprilike 85% do 87 % (određeno in vitro pri terapijskim koncentracijama lijeka) i stoga je mala vjerojatnost interakcije s drugim lijekovima zbog istiskivanja.
Elderly population (see section 4.2)
Starije osobe (vidjeti dio 4.2)
Ibandronic acid selectively inhibits osteoclast activity, reducing bone resorption and thereby reducing skeletal complications of the malignant disease.
Ibandronatna kiselina selektivno inhibira aktivnost osteoklasta, smanjujući resorpciju kostiju i time smanjuje koštane komplikacije zloćudnih bolesti.
Patients should pay particular attention and be able to comply with the dosing instructions (see section 4.2).
Bolesnici trebaju obratiti posebnu pozornost i pridržavati se uputa o doziranju (vidjeti dio 4.2).
Ibandronic Acid Teva is for use only by postmenopausal women and must not be taken by women who could still have a baby.
Ibandronatna kiselina Teva je namijenjena samo za žene u postmenopauzi i ne smiju je uzimati žene koje još mogu imati djecu.
The study enrolled women aged 55 to 80 years, who were at least 5 years postmenopausal, who had a BMD at lumbar spine of 2 to 5 SD below the premenopausal mean (T-score) in at least one vertebra [L1-L4], and who had one to four prevalent vertebral fractures.
U ispitivanju su bile uključene žene od 55 do 80 godina koje su bile u postmenopauzi najmanje pet godina i u kojih je BMD lumbalne kralježnice iznosio od 2 do 5 SD manje od premenopauzalne srednje vrijednosti (Tvrijednost) na barem jednom kralješku [L1-L4], a koje su imale od jednog do četiri postojeća prijeloma kralježaka.
The anti-fracture effect was consistent over the duration of the study.
Učinak na sprječavanje prijeloma bio je nepromijenjen za vrijeme trajanja ispitivanja.
• flatulence (farting, feeling bloated)
• nadutost (vjetrovi, osjećaj nadimanja)
The pain reduction was consistently below baseline throughout the entire study and accompanied by a significantly reduced use of analgesics compared to placebo.
Smanjenje boli bilo je tijekom cjelokupnog ispitivanja ispod početne vrijednosti i praćeno značajno smanjenom uporabom analgetika, u usporedbi s placebom.
Pharmacotherapeutic group: Medicinal products for treatment of bone diseases, bisphosphonate, ATC Code: M05BA06
Farmakoterapijska skupina: Pripravci za liječenje bolesti kostiju, bisfosfonati, ATK oznaka: M05BA06
Marketing Authorisation Holder and Manufacturer
Nositelj odobrenja za stavljanje u promet lijeka i proizvođač
The primary endpoint of the trials was the skeletal morbidity period rate (SMPR).
Primarna mjera ishoda ispitivanja bila je određivanje stope razdoblja s morbiditetom kostiju (SMPR; engl. skeletal morbidity period rate).
Oral bioavailability of ibandronic acid is generally reduced in the presence of food.
Bioraspoloživost peroralno uzete ibandronatne kiseline općenito je smanjena u prisutnosti hrane.
Total clearance of ibandronic acid is low with average values in the range 84-160 ml/min.
Ukupni je klirens ibandronatne kiseline nizak, s prosječnim vrijednostima u rasponu od 84-160 ml/min.
However, since this increase is within the normal variability of the bioavailability of ibandronic acid, no dose adjustment is considered necessary when Ibandronic Acid Teva is administered with H2-antagonists or other active substances which increase gastric pH.
Međutim, budući da je to povećanje u okviru normalne varijabilnosti bioraspoloživosti ibandronatne kiseline, prilagodba doze nije potrebna kada se Ibandronatna kiselina Teva primjenjuje s H2-antagonistima ili drugim lijekovima koji povećavaju pH želučane kiseline.